Unaided awareness of EMD Serono's Mavenclad (cladribine tablets) and Novartis' siponimod increased compared to previous quarters, but neurologists appear split on how, or if, they will incorporate the newest agents into their multiple sclerosis armamentarium, according to a new report from Spherix Global Insights